(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
Multi-million-euro win in Spanish lottery in doubt due to oversight- Venezuelan President Maduro arrives in New York following U.S. capture: Full coverage
- Poland identifies two Ukrainian suspects in railway sabotage blast
- A Manual for Pick Viable Psychological well-being Backing Administrations In 2024
- Vote In favor of Your Favored Cereal
- 6 Methods for further developing Rest Quality
- One spent $20 on candy. Another paid $700 for a custom costume. Here's how Halloween costs stacked up this year.
- Volcanic eruption led to the Black Death, new research suggests
- Must-Have Wellness Gear: What to Purchase for Successful Exercises
